Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: Zeta Potential Determination SOP – V 2.0

Posted on By

Analytical Method Development: Zeta Potential Determination SOP – V 2.0

Standard Operating Procedure for Zeta Potential Determination in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/117/2025
Supersedes SOP/AMD/117/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP defines the method for measuring zeta potential using electrophoretic light scattering (ELS) for pharmaceutical dispersions, nanoparticles, and colloidal systems in order to assess their physical stability and surface charge properties.

2. Scope

This procedure applies to the Analytical Method Development (AMD) laboratory for the characterization of formulations, APIs, and nanoformulations requiring evaluation of zeta potential in both research and product development stages.

3. Responsibilities

  • Analytical Scientist: Prepares samples, conducts measurements, and analyzes data.
  • Instrument Operator: Calibrates equipment and ensures maintenance logs are updated.
  • QA Officer: Reviews and verifies the records for GMP compliance.
  • Head – AMD: Approves method development and interpretation reports.
See also  Analytical Method Development: SOP for XRPD Method for Polymorph Characterization - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring method integrity, accuracy, and traceability in zeta potential determination processes.

5. Procedure

5.1 Instrument Preparation

  1. Power on the zeta potential analyzer (e.g., Malvern Zetasizer Nano ZS) and allow full system initialization.
  2. Use appropriate cuvette type (disposable or reusable capillary cell).
  3. Verify calibration using standard solutions (e.g., 0.1 mM KCl or certified latex particles).
  4. Log instrument verification in Annexure-1: Instrument Calibration Log.

5.2 Sample Preparation

  1. Disperse 1–10 mg of sample in 1–5 mL of electrolyte solution (1 mM KCl preferred).
  2. Use bath sonication (3–5 minutes) to ensure complete dispersion.
  3. Avoid air bubbles during transfer into the cuvette.
  4. Ensure pH measurement is recorded if pH-dependence is evaluated.
  5. Document all sample details in Annexure-2: Sample Preparation Log.

5.3 Measurement Conditions

  1. Enter method parameters in software:
    • Temperature: 25 ± 2°C
    • Voltage: 30–150 V (auto-adjust or manual)
    • Dispersant properties: viscosity and refractive index
  2. Run triplicate measurements and record average and standard deviation.
  3. Accept measurement if:
    • Polydispersity index (PDI) ≤ 0.3 (if DLS measured concurrently)
    • %RSD between replicates ≤ 10%
  4. Log results in Annexure-3: Zeta Potential Measurement Record.
See also  Analytical Method Development: SOP for Calibration of UV-Visible Spectrophotometer - V 2.0

5.4 Data Interpretation

  1. Evaluate zeta potential results for indication of physical stability:
    • |Zeta Potential| > 30 mV: High stability
    • ±20 to 30 mV: Moderate stability
    • ±10 to 20 mV: Low stability
    • < ±10 mV: Likely aggregation
  2. Document interpretation and observations in Annexure-4: Analysis Summary.

5.5 Cleaning and Maintenance

  1. Flush cells with water or ethanol depending on solvent used.
  2. Inspect for particle residues and clean with lint-free tissue.
  3. Log cleaning activity in Annexure-5: Post-Use Cleaning Record.

6. Abbreviations

  • ELS: Electrophoretic Light Scattering
  • PDI: Polydispersity Index
  • RSD: Relative Standard Deviation
  • pH: Potential of Hydrogen
  • SOP: Standard Operating Procedure

7. Documents

  1. Instrument Calibration Log – Annexure-1
  2. Sample Preparation Log – Annexure-2
  3. Zeta Potential Measurement Record – Annexure-3
  4. Analysis Summary – Annexure-4
  5. Post-Use Cleaning Record – Annexure-5

8. References

  • USP <729> – Globule Size Distribution in Lipid Injectable Emulsions
  • ICH Q6A – Specifications for New Drug Substances
  • Manufacturer’s User Manual – Malvern Zetasizer

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Instrument Calibration Log

Date Standard Used Result Performed By
18/05/2025 0.1 mM KCl Within range Rajesh Kumar

Annexure-2: Sample Preparation Log

Sample ID Electrolyte Concentration pH Prepared By
ZETA117-A 1 mM KCl 2 mg/mL 6.5 Sunita Reddy

Annexure-3: Zeta Potential Measurement Record

Run Zeta Potential (mV) RSD (%) Comments
1 -35.2 2.5 Stable

Annexure-4: Analysis Summary

The sample showed a zeta potential of -35.2 mV, indicating high colloidal stability and surface charge repulsion. The formulation is considered electrostatically stable.

Annexure-5: Post-Use Cleaning Record

Date Cuvette Type Solvent Used Cleaned By
18/05/2025 Disposable DTS1070 DI Water Sunita Reddy

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Added Annexures and clarified pH and PDI recording requirements Annual Review
See also  Analytical Method Development: Precipitation Reaction Based Method Development - V 2.0
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Elixir Department: SOP for Verification of Final Product Volume – V 2.0
Next Post: API Manufacturing: SOP for Audit Trail Review for GMP Systems – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version